NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, today announced financial results for the third quarter ended September 30, 2006.
